Roche’s breast cancer pill, which the company recently said had the potential to become its biggest-ever selling drug, has failed in what is arguably its most important Phase 3 trial. The ...
Legend Biotech has tapped Novartis executive Ingrid Zhang as its new CEO at a time when the company is seeking its next act.
Welcome back to another edition of Endpoints Weekly! We’ll get to the headlines in just a bit, but be sure to check out the ...
Six UK parliamentary committees ask the National Audit Office to probe the cost of the £1B UK-US pharma deal and its NHS ...
Gilead expands lenacapavir HIV PrEP access in Latin America; Cloudbreak IPO probed; Sironax gets $125M from Novartis; Circle ...
Endpoints takes its China biotech debate to DC: four Post-Hoc Live conversations on patents, FDA data, biosecurity and ...
CMS signaled drugmakers joining its Generous Medicaid rebate demo would be exempt from the Globe and Guard Medicare pilots, ...
CART01; Ori bags $120M deal; Reckitt invests $600M in US; Astellas expands Ireland; Hovione opens NJ facility.
FDA grants accelerated approval to Ultragenyx's Sanfilippo gene therapy UX111, weeks after the biotech's Angelman Phase 3 ...
An extended-release version of deucrictibant reduced patients’ mean monthly attack rate by 83% compared to placebo, meeting ...
Sionna Therapeutics announced it was laying off 46% of its staff as it seeks a way forward following an unexpected trial ...
The FDA approved a new combination regimen from Eli Lilly for certain breast cancer patients, a regimen that includes Lilly’s oral selective estrogen receptor degrader (SERD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results